E-therapeutics Regulatory News (ETX)

e-Therapeutics plc("e-Therapeutics" or the "Company")

Research and Development presentation to Investors and Analysts

Oxford and Newcastle, UK, 27 November 2014 - e-Therapeutics plc (AIM: ETX), the drug discovery and development company, announces that it will be holding an investor and analyst presentation and workshop today from 9.30am at its Oxford site.

The purpose of the site visit is to provide an update of the Company's discovery platform, discovery project pipeline, clinical development process and the current status of development for its drug candidates.

Highlights of the presentation will include:

· An overview of the experimental results of two new discovery projects: telomerase inhibition and compartmental neurodegeneration, which include data suggesting 10% or more of the screened compounds are active, and that in some instances substantially higher yields are observed. The Company believes that these hit-rates are higher than those typically reported from other discovery approaches, reflecting the use of network pharmacology to enhance selection of molecules with predicted activity characteristics.

· A summary of the current 'live' discovery projects, including five projects in both degenerative CNS disorders and oncology that are expected to generate activity data by the end of H1 2015.

· A synopsis of development activities including anticipated timelines for phase 1b studies for ETS2101, together with the range of possible phase II start times (which remain dependent on the outcomes of the various phase 1b cohort trials), and the current phase II study of ETS6103.

No material new information will be provided beyond what was disclosed at the recent half-year results.

- Ends -

Contacts:

e-Therapeutics plc

Steve Medlicott and Malcolm Young

Tel: +44 (0)1993 880 000

www.etherapeutics.co.uk

N+1 Singer

Aubrey Powell / Jen Boorer

Tel: +44 (0)20 7496 3000

www.n1singer.com 

Instinctif Partners

Melanie Toyne Sewell / Emma Barlow

Tel: +44 (0)20 7457 2020

Email: e-therapeutics@instinctif.com

About e-Therapeutics plc

e-Therapeutics is an AIM-quoted drug discovery and development company with a proprietary platform in network pharmacology, an innovative new approach to drug discovery based on advances in network science and chemical biology. The Company's discovery and development activity is currently focused in cancer and disorders of the nervous system.

e-Therapeutics is based at sites in Oxford and Newcastle, UK. For more information about the Company, please visit www.etherapeutics.co.uk.